Benzinga | Dec 8, 2021 07:30AM EST

EXCLUSIVE: Hoth Therapeutics Announces License Deal With Zyl Therapeutics To License Its Novel Cannabinoid Therapeutic, HT-005 For Lupus Patients, No Specific Terms Disclosed

NEW YORK, NY December 8, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ:

HOTH), a clinical-stage biopharmaceutical company focused on developing new generation

therapies for unmet medical needs, is pleased to announce that it has entered into an agreement

with Zyl? Therapeutics ("Zyl?") to license its novel cannabinoid therapeutic, HT-005 for lupus

patients, back to Zyl?.

Hoth's CEO, Robb Knie, stated "The licensing of HT-005 back to Zyl? after proving its efficacy

and safety in animals is a win-win for both companies. We are excited about Zyl?'s expertise in

the cannabinoid space and are pleased to receive both further equity in Zyl? and the potential

upside through royalties. Hoth will also reap cost savings, as Zyl? will be responsible for future

development cost."

Scott Pancoast, Zyl?'s CEO, stated, "Hoth has been a great partner, working closely with the

Zyl? team to confirm efficacy in an animal model and to strategize about the preclinical

development plan."

Therapeutic options for CLE are limited to steroids (topical and oral), topical calcineurin

inhibitors, and other immunomodulating therapies that could have adverse effects during long-

term use. Zyl? Therapeutics has developed a patented topical delivery system using xerogel-

derived particles called Z-pods(tm). Hoth had an exclusive license to develop HT-005, a drug that

targets the endocannabinoid pathway, encapsulated in the Z-pods(tm) to enhance absorption into

the skin. To investigate proof-of concept efficacy of HT-005 loaded Z-pods(tm), Zyl?

Therapeutics conducted a study in MRL/lpr mice, an established animal model that shows

symptoms similar to systemic lupus erythematosus (SLE) in humans. Results from the study

demonstrated that the novel HT-005 loaded Z-pods(tm) were effective in reducing skin plaques

associated with CLE, with statistical significance demonstrated in the overall average skin score

as well as individual skin scores on the head and scapula.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing

new generation therapies for unmet medical needs. Hoth's pipeline development is focused to

improve the quality of life for patients suffering from indications including atopic dermatitis,

skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, and

pneumonia. Hoth has also entered into two different agreements to further the development of

two therapeutic prospects to prevent or treat COVID-19. To learn more, please

visit www.hoththerapeutics.com.

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth's current expectations

which may constitute forward-looking statements for the purposes of the safe harbor provisions

under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and

are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's

business strategies; the timing of regulatory submissions; the ability to obtain and maintain

regulatory approval of existing product candidates and any other product candidates we may

develop, and the labeling under any approval we may obtain; the timing and costs of clinical

trials, the timing and costs of other expenses; market acceptance of our products; the ultimate

impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our

clinical trials, our research programs, healthcare systems or the global economy as a whole; our

intellectual property; our reliance on third party organizations; our competitive position; our

industry environment; our anticipated financial and operating results, including anticipated

sources of revenues; our assumptions regarding the size of the available market, benefits of our

products, product pricing, timing of product launches; management's expectation with respect to

future acquisitions; statements regarding our goals, intentions, plans and expectations, including

the introduction of new products and markets; and our cash needs and financing plans. There are

a number of factors that could cause actual events to differ materially from those indicated by

such forward-looking statements. You should not place reliance on these forward-looking

statements, which include words such as "could," "believe," "anticipate," "intend," "estimate,"

"expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such

terms or the negative of those terms. Although the Company believes that the expectations

reflected in the forward-looking statements are reasonable, the Company cannot guarantee such

outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual

results may differ materially from those indicated by these forward-looking statements as a result

of various important factors, including, without limitation, market conditions and the factors

described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-

K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such

statements speak only as of the date made. Consequently, forward-looking statements should be

regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue

reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of

activity, performance or achievements. Hoth does not undertake and specifically declines any

obligation to update, republish, or revise any forward-looking statements to reflect new

information, future events or circumstances or to reflect the occurrences of unanticipated events,

except as may be required by applicable law.